Trials / Completed
CompletedNCT01237496
Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253
Longitudinal Analysis of HBV-specific T Cell Responses in Patients With HBeAg-negative Chronic Hepatitis B (CHB) Treated With Pegylated Interferon Alfa-2a (40 KD) (Pegasys - RO258310). Immunology Sub-study of ML18253
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate immune responses in patients with HBeAg-negative chronic Hepatitis B treated with Pegasys (peginterferon alfa-2a). Eligible patients will have been randomized in study ML18253 to receive Pegasys 180 mcg subcutaneously for 48 or 96 weeks. Sample collection period for each patients will occur in the first 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | peginterferon alfa-2a [Pegasys] | 180 mcg sc weekly |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2010-11-09
- Last updated
- 2016-11-02
Locations
5 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT01237496. Inclusion in this directory is not an endorsement.